Zacks Investment Research lowered shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a sell rating in a research note released on Monday morning.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other equities research analysts also recently weighed in on AIMT. BidaskClub downgraded Aimmune Therapeutics from a buy rating to a hold rating in a report on Thursday, January 4th. Robert W. Baird assumed coverage on Aimmune Therapeutics in a report on Wednesday, December 20th. They set an outperform rating and a $64.00 price objective on the stock. ValuEngine downgraded Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Cantor Fitzgerald assumed coverage on Aimmune Therapeutics in a report on Tuesday, December 12th. They set an overweight rating and a $55.00 price objective on the stock. Finally, Wedbush reissued an outperform rating and set a $70.00 price objective on shares of Aimmune Therapeutics in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $55.43.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $39.00 on Monday. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $40.00. The firm has a market capitalization of $1,980.00 and a price-to-earnings ratio of -16.67.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities research analysts anticipate that Aimmune Therapeutics will post -2.51 earnings per share for the current year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,905 shares of Aimmune Therapeutics stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $33.00, for a total transaction of $62,865.00. Following the transaction, the insider now directly owns 1,905 shares of the company’s stock, valued at approximately $62,865. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen George Dilly sold 1,154 shares of Aimmune Therapeutics stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $26.24, for a total value of $30,280.96. The disclosure for this sale can be found here. Insiders have sold a total of 137,946 shares of company stock worth $4,991,189 over the last ninety days. Company insiders own 17.59% of the company’s stock.

Several hedge funds have recently bought and sold shares of AIMT. Citadel Advisors LLC raised its position in shares of Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after acquiring an additional 542,111 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Aimmune Therapeutics by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock worth $50,923,000 after acquiring an additional 276,978 shares in the last quarter. State Street Corp raised its position in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after acquiring an additional 228,429 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after acquiring an additional 132,603 shares in the last quarter. Finally, Palo Alto Investors LLC raised its position in shares of Aimmune Therapeutics by 9.9% in the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock worth $26,517,000 after acquiring an additional 116,221 shares in the last quarter. 73.34% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/zacks-investment-research-downgrades-aimmune-therapeutics-aimt-to-sell/1802556.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.